LEADER 00932nam a2200253 i 4500 001 991003900739707536 005 20020506110726.0 008 010315s1940 it ||| | ita 035 $ab10570822-39ule_inst 035 $aEXGIL128808$9ExL 040 $aBiblioteca Interfacoltà$bita 082 0 $a016.85090091 100 1 $aFalqui, Enrico$0446111 245 10$aPezze d'appoggio :$bappunti bibliografici sulla letteratura italiana contemporanea /$cEnrico Falqui 250 $a2. ed. aumentata 260 $aFirenze :$bLe Monnier,$c1940 300 $a174 p. ;$c19 cm. 650 4$aLetteratura italiana$ySec. 20. 907 $a.b10570822$b02-04-14$c27-06-02 912 $a991003900739707536 945 $aLE002 Fondo Bodini It. 544$g1$i2002000804044$lle002$o-$pE0.00$q-$rn$so $t0$u0$v0$w0$x0$y.i1065401x$z27-06-02 996 $aPezze d'appoggio$9235448 997 $aUNISALENTO 998 $ale002$b01-01-01$cm$da $e-$fita$git $h0$i1 LEADER 01537nam 2200397Ia 450 001 9910698867703321 005 20090512123704.0 035 $a(CKB)5470000002397187 035 $a(OCoLC)320838766 035 $a(EXLCZ)995470000002397187 100 $a20090512d2006 ua 0 101 0 $aeng 135 $auran||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aGuidance for industry$b[electronic resource] $esupplemental guidance on testing for replication competent retrovirus in reroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors 210 1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,$d[2006] 215 $ai, 13 pages $cdigital, PDF file 300 $aTitle from PDF title page (viewed on May, 12, 2009). 300 $a"November 2006." 320 $aIncludes bibliographical references (pages 10-11). 517 $aGuidance for industry 606 $aGene therapy$zUnited States$xTesting 606 $aRetroviruses$zUnited States 606 $aClinical trials$zUnited States 615 0$aGene therapy$xTesting. 615 0$aRetroviruses 615 0$aClinical trials 712 02$aCenter for Biologics Evaluation and Research (U.S.) 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910698867703321 996 $aGuidance for industry$93434577 997 $aUNINA